PANK-003 is under clinical development by First Condor Group and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PANK-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PANK-003 overview
PANK-003 is under development for the treatment of solid tumor. It comprises of allogeneic NK cell combined with postoperative standard adjuvant chemotherapy. It is based on PB-NK technology platform.
First Condor Group overview
First Condor Group is a biotechnology company that is involved in cell storage, production, research and development, and promotion in the fields of cell therapy. The company is headquartered in Dongguan, Guangdong, China.
For a complete picture of PANK-003’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.